News

ABL Awarded NIAID Contract to Develop Biotherapeutics to Address Infectious Disease

  • September 21, 2016

September 21, 2016 (Rockville, MD) – ABL, Inc. (ABL), a global contract research and manufacturing service provider to the U.S. Government and biopharmaceutical industry, announced today it is one of four prime contractors awarded a ten-year, indefinite delivery/indefinite quantity (ID/IQ) contract #HHSN272201600004I “Preclinical Services for Biopharmaceutical Product Development” by the Division of Microbiology and Infectious Diseases (DMID) within the National Institute of Allergy and Infectious Disease (NIAID).

The contract is part of a multiple award ID/IQ pool with a maximum ceiling of $159,444,814 to provide biopharmaceutical product development services for a wide range of critical global infectious disease issues including development of products against bioterrorism, drug resistance, emerging and re-emerging pathogens, and infectious diseases in developing areas of the world. ABL will provide NIAID with a comprehensive portfolio of services including product development planning, process and bioanalytical assay development, cGMP manufacturing and release of drug product, and regulatory support for promising biopharmaceutical therapeutics and diagnostics leading to Investigational New Drug (IND) applications, Biologics License Applications (BLA) or other FDA submissions.

“This award expands ABL’s support of DMID’s vital gap-filling product development programs that are crucial to tackling some of the most urgent global public health issues we face today,” explains Dr. Thomas VanCott, President and CEO of ABL. “From food borne pathogens like Shigella, to emerging disease agents like Ebola and Zika viruses, ABL continues to put its significant infectious disease resources to work helping advance novel therapies and diagnostics into the clinic and beyond.”